Portal de Periódicos da CAPES

Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men

2003; Lippincott Williams & Wilkins; Volume: 107; Issue: 11 Linguagem: Inglês

10.1161/01.cir.0000060815.25798.02

1524-4539

Michael Schoppet, Juergen R. Schaefer, Lorenz C. Hofbauer,

Bone health and osteoporosis research

HomeCirculationVol. 107, No. 11Low Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men Free AccessLetterPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessLetterPDF/EPUBLow Serum Levels of Soluble RANK Ligand Are Associated With the Presence of Coronary Artery Disease in Men Michael Schoppet, MD, Juergen R. Schaefer, MD and Lorenz C. Hofbauer, MD Michael SchoppetMichael Schoppet Department of Internal Medicine, Philipps-University, Marburg, Germany , Juergen R. SchaeferJuergen R. Schaefer Department of Internal Medicine, Philipps-University, Marburg, Germany and Lorenz C. HofbauerLorenz C. Hofbauer Department of Internal Medicine, Philipps-University, Marburg, Germany Originally published25 Mar 2003https://doi.org/10.1161/01.CIR.0000060815.25798.02Circulation. 2003;107:e76To the Editor:Receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) represent the ligand and decoy receptor, respectively, of a pleiotropic cytokine system that regulates bone metabolism and vascular biology.1 Elevated OPG serum levels have recently been shown to be associated with increased cardiovascular mortality in postmenopausal women.2 In the September 3, 2002 issue of Circulation, Jono et al3 reported increased OPG serum levels in 201 Japanese patients with coronary artery disease (CAD) and a positive correlation of OPG serum levels with the severity of CAD. In a cohort of 522 white men who underwent coronary angiography, we have confirmed that OPG serum levels are highest in those with advanced CAD,4 indicating that these findings are independent of geographic and ethnic differences.However, because OPG acts by neutralizing the ligand, RANKL, we hypothesized that serum levels of soluble RANKL (sRANKL) are also altered in CAD. To test this hypothesis, we assessed sRANKL serum levels in a well-characterized cohort consisting of 346 age-matched white men (mean age 59.7±8.8 years) undergoing coronary angiography for suspected CAD. Of those, 106 men had no coronary or luminal irregularities, and 240 patients were found to have CAD. Serum levels of sRANKL were measured by an ELISA system (Biomedica) that detects free sRANKL, but not sRANKL complexed to OPG. Soluble RANKL serum levels were significantly lower in patients with CAD (0.50±0.56 pmol/l) compared with those without CAD (0.60±0.60 pmol/l, P=0.009), but in contrast to OPG serum levels, were not correlated with the severity of CAD. Moreover, sRANKL serum levels were not correlated with age, creatinine serum concentrations, body mass index, or the presence of diabetes, arterial hypertension, or hyperlipidemia. They were, however, correlated negatively with OPG serum levels (r=−0.19, P=0.01).Thus, although OPG serum levels increase with progression of CAD,3,4 our data indicate that sRANKL serum levels are lower in patients with CAD. These concurrent changes of sRANKL and OPG result in a net decrease of the RANKL-to-OPG ratio. Because a high RANKL-to-OPG ratio is associated with profound arterial calcification in OPG-deficient mice that can be rescued by administration of an OPG transgene,5 the findings of low sRANKL-to-OPG ratios in men with CAD are unexpected, and may represent an insufficient counter-regulatory mechanism that needs to be further evaluated.We thank Alexander Sattler, MD, Marburg, for his support.1 Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet. 2001; 358: 257–259.CrossrefMedlineGoogle Scholar2 Browner WS, Lui LY, Cummings CR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001; 86: 631–637.MedlineGoogle Scholar3 Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106: 1192–1194.LinkGoogle Scholar4 Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003; 88: 1024–1028.CrossrefMedlineGoogle Scholar5 Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000; 192: 463–474.CrossrefMedlineGoogle ScholarcirculationahaCirculationCirculationCirculation0009-73221524-4539Lippincott Williams & WilkinsResponseJono Shuichi, , MD, Mori Katsuhito, , MD, Nishizawa Yoshiki, , MD, Shioi Atsushi, , MD, Miki Takami, , MD, Ikari Yuji, , MD, and Hara Kazuhiro, , MD25032003We thank Drs Schoppet, Schaefer, and Hofbauer for their comments about our study of the association between serum osteoprotegerin (OPG) levels and the severity of coronary artery disease (CAD)1. They have confirmed that serum OPG levels are significantly greater in patients with advanced CAD than in those without CAD. Interestingly, they found that the serum levels of soluble receptor activator of nuclear factor-κB ligand (RANKL) were significantly lower in patients with CAD than in those without CAD, and that serum soluble RANKL levels were correlated with serum OPG levels. In histological study, RANKL and OPG immunoreactivity was demonstrated in the nondiseased vessel wall and in the early atherosclerotic lesions in human tissues.2 RANKL was present in the extracellular matrix surrounding the calcium mineral deposits of the plaques. Moreover, RANKL transcripts are detected in the calcified arteries of OPG deficient mice.3 These findings suggest that RANKL may be involved in the regulation of mineralization in atherosclerotic lesions. The RANKL/OPG system may have an important role in the regulation of vascular disease. RANKL, OPG, and RANKL-to-OPG ratio measurement in the serum may help to evaluate the activity of vascular disease. Previous Back to top Next FiguresReferencesRelatedDetailsCited By Czerwińska K, Poręba M, Prokopowicz A, Januszewska L, Jaremków A, Markiewicz-Górka I, Martynowicz H, Mazur G, Poręba R, Pawlas K and Gać P (2022) Association Between Serum Selenium Concentration and OPG/RANKL/RANK Axis in Patients with Arterial Hypertension, Cardiovascular Toxicology, 10.1007/s12012-022-09741-x, 22:7, (620-630), Online publication date: 1-Jul-2022. Celebi G, Anapali M, Dagistanli F, Akdemir A, Aydemir D, Ulusu N, Ulutin T and Komurcu-Bayrak E (2021) Effect of vitamin D supplementation on OPG/RANKL signalling activities in endothelial tissue damage in diet-induced diabetic rat model, Pharmacological Reports, 10.1007/s43440-021-00332-1, 74:1, (124-134), Online publication date: 1-Feb-2022. Wu P, Lin Y, Chen C, Chiu Y, Tsai J, Kuo P, Hsu Y, Ljunggren Ö, Fellström B and Kuo M (2020) Associations of Bone Turnover Markers with Cognitive Function in Patients Undergoing Hemodialysis, Disease Markers, 10.1155/2020/8641749, 2020, (1-10), Online publication date: 24-Apr-2020. Zampetti S, Lucantoni F, Pacifico L, Campagna G, Versacci P, Pierimarchi P and Buzzetti R (2018) Association of OPG–RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths, Journal of Endocrinological Investigation, 10.1007/s40618-018-0932-y, 42:4, (427-434), Online publication date: 1-Apr-2019. Cudrici C, Ferrante E and Boehm M (2019) Basic molecular mechanism of vascular calcification Coronary Calcium, 10.1016/B978-0-12-816389-4.00003-7, (47-82), . Znorko B, Oksztulska-Kolanek E, Michałowska M, Kamiński T and Pawlak K (2017) Does the OPG/RANKL system contribute to the bone-vascular axis in chronic kidney disease? A systematic review, Advances in Medical Sciences, 10.1016/j.advms.2016.08.001, 62:1, (52-64), Online publication date: 1-Mar-2017. Arslan M, Tutal E, Sahin M, Karakose M, Ucan B, Ozturk G, Cakal E, Biyikli Gencturk Z, Ozbek M and Delibasi T (2016) Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes, Endocrine, 10.1007/s12020-016-1121-4, 55:2, (410-415), Online publication date: 1-Feb-2017. Saha H, Mukherjee B, Bindhani B and Ray M (2015) Changes in RANKL and osteoprotegerin expression after chronic exposure to indoor air pollution as a result of cooking with biomass fuel, Journal of Applied Toxicology, 10.1002/jat.3275, 36:7, (969-976), Online publication date: 1-Jul-2016. Kang K (2015) Low bone mineral density is associated with intracranial posterior circulation atherosclerosis in women, Bone, 10.1016/j.bone.2015.09.016, 81, (669-674), Online publication date: 1-Dec-2015. Gaudio A, Muratore F, Fiore V, Rapisarda R, Signorelli S and Fiore C (2015) Decreased bone cortical density at the forearm in subjects with subclinical peripheral arterial disease, Osteoporosis International, 10.1007/s00198-015-3057-6, 26:6, (1747-1753), Online publication date: 1-Jun-2015. Faienza M, Luce V, Ventura A, Colaianni G, Colucci S, Cavallo L, Grano M and Brunetti G (2015) Skeleton and Glucose Metabolism: A Bone-Pancreas Loop, International Journal of Endocrinology, 10.1155/2015/758148, 2015, (1-7), . Samelson E, Miller P, Christiansen C, Daizadeh N, Grazette L, Anthony M, Egbuna O, Wang A, Siddhanti S, Cheung A, Franchimont N and Kiel D (2014) RANKL Inhibition With Denosumab Does Not Influence 3-Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High Cardiovascular Risk, Journal of Bone and Mineral Research, 10.1002/jbmr.2043, 29:2, (450-457), Online publication date: 1-Feb-2014. Irtyuga O, Zhiduleva E, Kazakova E and Moiseeva O (2013) PATHOGENESIS OF AORTIC STENOSIS IN HYPERTENSIVE PATIENTS, "Arterial'naya Gipertenziya" ("Arterial Hypertension"), 10.18705/1607-419X-2013-19-6-495-501, 19:6, (495-501) Di Bartolo B, Cartland S, Harith H, Bobryshev Y, Schoppet M, Kavurma M and Kocher O (2013) TRAIL-Deficiency Accelerates Vascular Calcification in Atherosclerosis via Modulation of RANKL, PLoS ONE, 10.1371/journal.pone.0074211, 8:9, (e74211) Kelesidis T, Kendall M, Yang O, Hodis H and Currier J (2013) Perturbations of Circulating Levels of RANKL-Osteoprotegerin Axis in Relation to Lipids and Progression of Atherosclerosis in HIV-Infected and -Uninfected Adults: ACTG NWCS 332/A5078 Study, AIDS Research and Human Retroviruses, 10.1089/aid.2012.0305, 29:6, (938-948), Online publication date: 1-Jun-2013. Morony S, Sage A, Corbin T, Lu J, Tintut Y and Demer L (2012) Enhanced Mineralization Potential of Vascular Cells from SM22α-Rankl tg Mice, Calcified Tissue International, 10.1007/s00223-012-9655-9, 91:6, (379-386), Online publication date: 1-Dec-2012. Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, Unsal A and Yildiz A (2012) Osteoprotegerin/RANKL Axis and Progression of Coronary Artery Calcification in Hemodialysis Patients, Clinical Journal of the American Society of Nephrology, 10.2215/CJN.11191111, 7:6, (965-973), Online publication date: 1-Jun-2012. Pirih F, Lu J, Ye F, Bezouglaia O, Atti E, Ascenzi M, Tetradis S, Demer L, Aghaloo T and Tintut Y (2012) Adverse effects of hyperlipidemia on bone regeneration and strength, Journal of Bone and Mineral Research, 10.1002/jbmr.541, 27:2, (309-318), Online publication date: 1-Feb-2012. Ashley D, O'Sullivan E, Davenport C, Devlin N, Crowley R, McCaffrey N, Moyna N, Smith D and O'Gorman D (2011) Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects, Metabolism, 10.1016/j.metabol.2010.10.001, 60:7, (994-1000), Online publication date: 1-Jul-2011. Demer L, Tintut Y and Towler D (2011) The Roles of Lipid Oxidation Products and Receptor Activator of Nuclear Factor-κB Signaling in Atherosclerotic Calcification , Circulation Research, 108:12, (1482-1493), Online publication date: 10-Jun-2011.Byon C, Sun Y, Chen J, Yuan K, Mao X, Heath J, Anderson P, Tintut Y, Demer L, Wang D and Chen Y (2011) Runx2-Upregulated Receptor Activator of Nuclear Factor κB Ligand in Calcifying Smooth Muscle Cells Promotes Migration and Osteoclastic Differentiation of Macrophages, Arteriosclerosis, Thrombosis, and Vascular Biology, 31:6, (1387-1396), Online publication date: 1-Jun-2011. Pennisi P, Russo E, Gaudio A, Veca R, D'Amico F, Mangiafico R, Laspina M, Tringali G, Signorelli S and Fiore C (2010) The association between carotid or femoral atherosclerosis and low bone mass in postmenopausal women referred for osteoporosis screening. Does osteoprotegerin play a role?, Maturitas, 10.1016/j.maturitas.2010.07.013, 67:4, (358-362), Online publication date: 1-Dec-2010. Lieb W, Gona P, Larson M, Massaro J, Lipinska I, Keaney J, Rong J, Corey D, Hoffmann U, Fox C, Vasan R, Benjamin E, O'Donnell C and Kathiresan S (2010) Biomarkers of the Osteoprotegerin Pathway, Arteriosclerosis, Thrombosis, and Vascular Biology, 30:9, (1849-1854), Online publication date: 1-Sep-2010. O'Sullivan E, Ashley D, Davenport C, Devlin N, Crowley R, Agha A, Thompson C, O'Gorman D and Smith D (2010) Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes, Diabetes/Metabolism Research and Reviews, 10.1002/dmrr.1109, 26:6, (496-502), Online publication date: 1-Sep-2010. Venuraju S, Yerramasu A, Corder R and Lahiri A (2010) Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity, Journal of the American College of Cardiology, 10.1016/j.jacc.2010.03.013, 55:19, (2049-2061), Online publication date: 1-May-2010. Klejna K, Naumnik B, Gasowska K and Myśliwiec M (2009) OPG/RANK/RANKL signaling system and its significance in nephrology., Folia Histochemica et Cytobiologica, 10.2478/v10042-009-0035-x, 47:2 Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E and Valdivielso J (2009) RANKL Increases Vascular Smooth Muscle Cell Calcification Through a RANK-BMP4–Dependent Pathway, Circulation Research, 104:9, (1041-1048), Online publication date: 8-May-2009. Frost M, Grella R, Millasseau S, Jiang B, Hampson G, Fogelman I and Chowienczyk P (2008) Relationship of Calcification of Atherosclerotic Plaque and Arterial Stiffness to Bone Mineral Density and Osteoprotegerin in Postmenopausal Women Referred for Osteoporosis Screening, Calcified Tissue International, 10.1007/s00223-008-9153-2, 83:2, (112-120), Online publication date: 1-Aug-2008. Choi B, Vilahur G, Cardoso L, Fritton J, Ibanez B, Zafar M, Yadegar D, Speidl W, Schaffler M, Fuster V and Badimon J (2008) Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway, European Journal of Clinical Investigation, 10.1111/j.1365-2362.2008.01930.x, 38:4, (211-217), Online publication date: 1-Apr-2008. Mangiafico R, Alagona C, Pennisi P, Parisi N, Mangiafico M, Purrello F and Fiore C (2007) Increased augmentation index and central aortic blood pressure in osteoporotic postmenopausal women, Osteoporosis International, 10.1007/s00198-007-0438-5, 19:1, (49-56), Online publication date: 1-Jan-2008. An J, Han D, Kim D, Kim S, Rhee Y, Lee E and Lim S (2007) Expression and Regulation of Osteoprotegerin in Adipose Tissue, Yonsei Medical Journal, 10.3349/ymj.2007.48.5.765, 48:5, (765), . Montecucco F, Steffens S and Mach F (2007) The Immune Response Is Involved in Atherosclerotic Plaque Calcification: Could the RANKL/RANK/OPG System Be a Marker of Plaque Instability?, Clinical and Developmental Immunology, 10.1155/2007/75805, 2007, (1-8), . Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S and Zauli G (2006) An Increased Osteoprotegerin Serum Release Characterizes the Early Onset of Diabetes Mellitus and May Contribute to Endothelial Cell Dysfunction, The American Journal of Pathology, 10.2353/ajpath.2006.060398, 169:6, (2236-2244), Online publication date: 1-Dec-2006. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J and Schett G (2014) The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease, Expert Review of Cardiovascular Therapy, 10.1586/14779072.4.6.801, 4:6, (801-811), Online publication date: 1-Nov-2006. Schoppet M, Sattler A, Schaefer J and Hofbauer L (2006) Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis, Atherosclerosis, 10.1016/j.atherosclerosis.2005.10.028, 184:2, (446-447), Online publication date: 1-Feb-2006. Bezerra M, Calomeni G, Caparbo V, Gebrim E, Rocha M and Pereira R (2005) Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis, Rheumatology, 10.1093/rheumatology/kei045, 44:12, (1503-1506), Online publication date: 1-Dec-2005. Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, Raffa S, D'Anneo G, Lucà F, Mioni C, Arrigo F and Squadrito F (2005) Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction, Clinical Science, 10.1042/CS20050058, 109:4, (389-395), Online publication date: 1-Oct-2005. RHEE E, LEE W, KIM S, KIM B, SUNG K, KIM B, KANG J, OH K, OH E, BAEK K, KANG M, WOO H, PARK H, KIM S, LEE M and PARK J (2005) Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein, Clinical Science, 10.1042/CS20040255, 108:3, (237-243), Online publication date: 1-Mar-2005. Lim S and Park S (2005) Osteoporosis and Atherosclerosis: Current and New Potential Medicines Targeting Both Diseases, Journal of Korean Society of Endocrinology, 10.3803/jkes.2005.20.6.608, 20:6, (608), . Hruska K, Saab G, Chaudhary L, Quinn C, Lund R and Surendran K (2004) Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy, Seminars in Nephrology, 10.1053/j.semnephrol.2003.08.010, 24:1, (25-38), Online publication date: 1-Jan-2004. March 25, 2003Vol 107, Issue 11 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000060815.25798.02PMID: 12654623 Originally publishedMarch 25, 2003 PDF download Advertisement